uniQure to Announce Second Quarter 2025 Financial Results
uniQure (NASDAQ: QURE), a leading gene therapy company, will release its second quarter 2025 financial results before market open on Tuesday, July 29, 2025. The company will host a conference call and webcast at 8:30 a.m. ET to discuss the results.
The earnings call will be accessible via webcast through uniQure's website under the Events & Presentations section, with a replay available for 90 days. Phone participants must pre-register online to receive dial-in details and are advised to join 15 minutes before the start time.
uniQure (NASDAQ: QURE), un'azienda leader nella terapia genica, pubblicherà i suoi risultati finanziari del secondo trimestre 2025 prima dell'apertura del mercato di martedì 29 luglio 2025. La società terrà una conference call e un webcast alle 8:30 a.m. ET per discutere i risultati.
La chiamata per gli utili sarà accessibile tramite webcast sul sito web di uniQure nella sezione Eventi e Presentazioni, con una replica disponibile per 90 giorni. I partecipanti telefonici devono preregistrarsi online per ricevere i dettagli di accesso e si consiglia di collegarsi 15 minuti prima dell'inizio.
uniQure (NASDAQ: QURE), una empresa líder en terapia génica, publicará sus resultados financieros del segundo trimestre de 2025 antes de la apertura del mercado el martes 29 de julio de 2025. La compañía realizará una conferencia telefónica y una transmisión en vivo a las 8:30 a.m. ET para discutir los resultados.
La llamada de ganancias será accesible vía webcast a través del sitio web de uniQure en la sección de Eventos y Presentaciones, con una repetición disponible durante 90 días. Los participantes telefónicos deben preregistrarse en línea para recibir los detalles de acceso y se recomienda unirse 15 minutos antes del inicio.
uniQure (NASDAQ: QURE)는 선도적인 유전자 치료 회사로서 2025년 2분기 재무 결과를 2025년 7월 29일 화요일 시장 개장 전에 발표할 예정입니다. 회사는 결과를 논의하기 위해 동부 표준시 오전 8시 30분에 컨퍼런스 콜 및 웹캐스트를 진행합니다.
실적 발표 콜은 uniQure 웹사이트의 이벤트 및 프레젠테이션 섹션을 통해 웹캐스트로 접속할 수 있으며, 재방송은 90일 동안 제공됩니다. 전화 참가자는 접속 정보를 받기 위해 사전 등록을 온라인으로 해야 하며, 시작 15분 전에 접속하는 것이 권장됩니다.
uniQure (NASDAQ: QURE), une entreprise leader dans la thérapie génique, publiera ses résultats financiers du deuxième trimestre 2025 avant l'ouverture du marché le mardi 29 juillet 2025. La société organisera une conférence téléphonique et un webcast à 8h30 ET pour discuter des résultats.
L'appel aux résultats sera accessible via webcast sur le site web de uniQure dans la section Événements & Présentations, avec une rediffusion disponible pendant 90 jours. Les participants téléphoniques doivent s'inscrire en ligne à l'avance pour recevoir les détails d'accès et sont invités à se connecter 15 minutes avant le début.
uniQure (NASDAQ: QURE), ein führendes Unternehmen im Bereich der Gentherapie, wird seine Finanzergebnisse für das zweite Quartal 2025 vor Börsenbeginn am Dienstag, den 29. Juli 2025 veröffentlichen. Das Unternehmen wird um 8:30 Uhr ET eine Telefonkonferenz und einen Webcast abhalten, um die Ergebnisse zu besprechen.
Der Gewinnaufruf ist über einen Webcast auf der Website von uniQure im Bereich Veranstaltungen & Präsentationen zugänglich, mit einer Wiederholung, die 90 Tage verfügbar ist. Telefonteilnehmer müssen sich online vorregistrieren, um die Einwahldaten zu erhalten, und werden gebeten, 15 Minuten vor Beginn beizutreten.
- None.
- None.
uniQure to host earnings call on Tuesday, July 29, 2025 at 8:30 a.m. ET
LEXINGTON, Mass. and AMSTERDAM, July 22, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs will report second quarter 2025 financial results before market open on Tuesday, July 29, 2025. Management will then host a conference call at 8:30 a.m. ET.
The event will be webcast under the Events & Presentations section of uniQure’s website at https://www.uniqure.com/investors-media/events-presentations, and following the event a replay will be archived for 90 days. Interested parties participating by phone will need to register using this online form. After registering for dial-in details, all phone participants will receive an auto-generated e-mail containing a link to the dial-in number along with a personal PIN number to use to access the event by phone. If you are joining the conference call, please dial in 15 minutes before the start time.
About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. The approvals of uniQure’s gene therapy for hemophilia B – an historic achievement based on more than a decade of research and clinical development – represent a major milestone in the field of genomic medicine and ushers in a new treatment approach for patients living with hemophilia. uniQure is now advancing a pipeline of proprietary gene therapies for the treatment of patients with Huntington's disease, refractory temporal lobe epilepsy, ALS, Fabry disease, and other severe diseases. www.uniQure.com
uniQure Contacts:
| FOR INVESTORS: Chiara Russo Direct: 781-491-4371 Mobile: 617-306-9137 c.russo@uniQure.com | FOR MEDIA: Tom Malone Direct: 339-970-7558 Mobile:339-223-8541 t.malone@uniQure.com |
FAQ
When will uniQure (QURE) report Q2 2025 earnings?
What time is uniQure's Q2 2025 earnings call?
How can investors access uniQure's Q2 2025 earnings call?
Where can I find the webcast of uniQure's Q2 2025 earnings call?
